To assess the affinity of the junction neopeptides formed by the KIF5B-RET fusion gene expressed and presented by the tumor, we employed two sequence-based in-silico HLA affinity prediction pipelines and a pipeline to examine Class I HLA affinity from a structural standpoint (9, 49). This evidence concerns the gene KIF5B and neoplasm.